December 15, 2021

Company name:

SanBio Co., Ltd.

Representative:

Keita Mori, Representative Director

and President

(TSE Mothers Code: 4592)

Contact:

Yoshihiro Kakutani, Corporate Officer

of Management Administration

(TEL. +81-3-6264-3481)

Notice on Conclusion of Committed Credit Line Agreement with Resona Bank, Ltd.

SanBio Company Limited (hereafter, "the Company") hereby announces that today it entered into a committed credit line agreement with Resona Bank, Ltd.

For its SB623 development program in Japan targeting chronic effects of traumatic brain injury, the Company has been consulting with the Pharmaceuticals and Medical Devices Agency (PMDA) under the framework of Sakigake (expedited review) Designation System with the aim of applying for approval as soon as possible. The funds obtained based on the terms of the agreement are scheduled to be allocated to the establishment of post-launch manufacture, distribution, and marketing infrastructure for SB623, assuming approval is granted.

Total committed

Agreement

Expiration date

Funding method

amount (of which, used

Remarks

date

(repayment date)

credit)

Committed credit

1.0 billion yen

December

June 2023

The committed credit line will

line

(none)

2021

(June 2023)

commence on January 14, 2022.

Main conditions of the agreement:

During the terms of the

agreement, the Company must

maintain net assets and after-tax

income above their corresponding

amounts indicated in the business

plan the Company submitted.

This development is expected to have only a marginal impact on the Company Group's consolidated

earnings performance for the fiscal year ending January 2022.

1

References

Summary of fund procurement

Counterparty

Funding method

Amount of funds

Agreement (or

Use of funds

(lender)

procured

approval) date

MUFG Bank, Ltd.

Committed credit

2.0 billion yen

Aug. 2021

Establishment of post-launch

line

manufacture, distribution, and

marketing infrastructure for SB623

Total 2.0 billion

yen

Counterparty

Funding method

Amount of funds

Agreement (or

Use of funds

(lender)

procured

approval) date

Mizuho Bank, Ltd.

Committed credit

2.0 billion yen

Dec. 2020

-

Establishment of post-launch

line with an option

manufacture, distribution, and

to extend the term

marketing infrastructure for SB623

of the loan

Mizuho Bank

Term loan with a

2.6 billion yen

Dec. 2020

-

Establishment of post-launch

commitment period

manufacture, distribution, and

marketing infrastructure for SB623

Total 4.6 billion

yen

Counterparty

Funding method

Amount of funds

Agreement (or

Use of funds

(lender)

procured

approval) date

Equity financing

7.1 billion yen

- Increase in the number of contract

(accelerated book

manufacturers to enhance mass

building [ABB])

production capabilities in

anticipation of higher demand in

Europe and the US

- Manufacturing to build inventory

of SB623 for chronic effects of

traumatic brain injury in Japan

Counterparty

Funding method

Amount of funds

Agreement (or

Use of funds

(lender)

procured

approval) date

Mizuho Bank

Committed credit

2.0 billion yen

Dec. 2018*1

-

Establishment of post-launch

line

manufacture, distribution, and

marketing infrastructure for SB623

MUFG Bank

Committed credit

2.0 billion yen

Nov. 2018*1

-

Establishment of post-launch

line

manufacture, distribution, and

marketing infrastructure for SB623

Sumitomo Mitsui

Committed credit

1.0 billion yen

Nov. 2018*1

-

Establishment of post-launch

Banking Corp.

line

manufacture, distribution, and

marketing infrastructure for SB623

Equity financing

11.0 billion yen

-

Establishment of post-launch

(warrants with a

manufacture, distribution, and

provision to revise

marketing infrastructure for SB623

exercise price, via

- Development of SB623 for chronic

2

third-party

effects of ischemic stroke in Japan,

allotment)

and R&D to expand development

regions for the drug with an eye

toward future sales

- R&D to expand indications for

SB623 and to in-license new

substances

Total 16.0 billion

yen

Counterparty

Funding method

Amount of funds

Agreement (or

Use of funds

(lender)

procured

approval) date

MUFG Bank*2

Loan

900 million yen

Mar. 2017

- Development of SB623 for chronic

effects of ischemic stroke in the

US, and for chronic effects of

traumatic brain injury in Japan and

the US

California Institute

Subsidy

19 million US

Jun. 2017

- Development of SB623 for chronic

for Regenerative

dollars

effects of ischemic stroke in the US

Medicine (CIRM)

Mizuho Bank

Committed credit

1.6 billion yen

Aug. 2017*1

- Reserve for development of SB623

line

for chronic effects of traumatic

brain injury in Japan and the US

MUFG Bank*2

Committed credit

500 million yen

Oct. 2017*1

- Reserve for development of SB623

line

for chronic effects of traumatic

brain injury in Japan and the US

Total 5.09 billion

yen

Counterparty

Funding method

Amount of funds

Agreement (or

Use of funds

(lender)

procured

approval) date

Mizuho Bank

Committed credit

1.0 billion yen

Mar. 2016*1

Reserve for development of SB623

line

for chronic effects of traumatic brain

injury in Japan and the US

Note 1: As of December 15, these agreements had expired as their terms had come to an end.

Note 2: Due to restructuring by function of Mitsubishi UFJ Financial Group, Inc., the counterparty (lender) was changed from Mitsubishi UFJ Trust and Banking Corp. to MUFG Bank, Ltd.

3

Attachments

  • Original Link
  • Original Document
  • Permalink

Disclaimer

SanBio Co. Ltd. published this content on 15 December 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 15 December 2021 07:08:02 UTC.